Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Share News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Wed, 06th Jan 2021 14:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

River & Mercantile Group PLC - Hires Martin Gilbert to be deputy chair, starting Wednesday. Gilbert was the co-founder and then chief executive of Aberdeen Asset Management, now Standard Life Aberdeen PLC. He currently is chair of lender Revolut Ltd and senior independent director of miner Glencore PLC. "In the current environment there are market opportunities for RMG, both organic and through acquisitions, that can drive shareholder value," Gilbert says. River & Mercantile had GBP45.4 billion in assets under management as of September 30.

----------

Fulcrum Utility Services Ltd - Sheffield-based multi-utility infrastructure and services provider - Daren Harris steps down as chief executive officer and from board, effective immediately. Chief Operating Officer Terry Dugdale, in post since March 2019, becomes CEO. "The business is well placed with strong market drivers and a robust balance sheet and its strategy is strongly positioned to capitalise on the UK's journey to net zero," Harris says. "Unfortunately, due to personal reasons, I need to step down from the business." He adds: "Since joining the business, Terry has driven our operating efficiency and has made significant progress in preparing the business foundations for the future."

----------

Silence Therapeutics PLC - London-based novel short interfering ribonucleic acid therapeutics developer - Hires Craig Tooman as chief financial officer, effective immediately. Tooman was most recently CFO & COO of Princeton, New Jersey-based Vyome Therapeutic Inc. Silence also says Michael Davidson has joined the Silence board as non-executive director. Davidson currently is CEO of New Amsterdam Pharma BV and a professor of medicine at the Lipid Clinic at the University of Chicago. He founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca PLC in 2013, and was founding CEO of Corvidia Therapeutics, which was acquired by Novo Nordisk AS in 2020.

----------

Personal Group Holdings PLC - Milton Keynes, Buckinghamshire-based provider of employee services - Makes Interim CFO Sarah Mace its permanent CFO, effective immediately. Mace was promoted to the board as interim CFO back in October, having joined Personal Group in 2014.

----------

Kape Technologies PLC - Isle of Man-based digital security and privacy software company - Hires Pierre-Etienne Lallia as non-executive director, effective immediately. Lallia spent 10 years at Nomura International PLC in London, where he was managing director of the Acquisition & Leveraged Finance team. Prior to that, he was with Goldman Sachs International, part of Goldman Sachs Group Inc.

----------

Time Finance PLC - Bath, England-based finance provider to UK small and medium businesses - Non-Executive Chair John Newman and CEO Ian Smith both to retire once successors are found. Says process for replacing the pair is underway. Says Smith's decision follows rebranding of company from 1pm PLC early last month and his previous intention to retire in any event at the end of 2021.

----------

Destiny Pharma PLC - Brighton-based clinical stage biotechnology firm focused on preventing infections - Hires Stephanie Bewick as chief business officer. Bewick was vice president for Business Development at Nasdaq-listed Summit Therapeutics Inc.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
26 Nov 2021 12:59

IN BRIEF: Silence Therapeutics to delist from AIM next week

IN BRIEF: Silence Therapeutics to delist from AIM next week

Read more
26 Nov 2021 09:53

Silence Therapeutics to proceed with AIM delisting next week

(Sharecast News) - Silence Therapeutics updated the market on the planned cancellation of its shares on AIM on Friday, which it originally announced on 15 October.

Read more
16 Nov 2021 12:23

TRADING UPDATES: Focusrite profit jumps; Gear4Music strikes bum note

TRADING UPDATES: Focusrite profit jumps; Gear4Music strikes bum note

Read more
16 Nov 2021 11:39

Revenue, expenses rise in third quarter for Silence Therapeutics

(Sharecast News) - Silence Therapeutics said on Tuesday that its revenue increased by £1.2m year-on-year in its third quarter, as a result of the further advancement of its partner programmes, as well as the introduction of additional programmes with its partners.

Read more
5 Nov 2021 18:40

IN BRIEF: Frazier Life picks up 3% interest in Silence Therapeutics

IN BRIEF: Frazier Life picks up 3% interest in Silence Therapeutics

Read more
5 Nov 2021 11:39

Frazier Life Sciences becomes 'important' new Silence Therapeutics shareholder

(Sharecast News) - Novel short interfering ribonucleic acid (siRNA) therapy developer Silence Therapeutics announced on Friday that healthcare-focussed investor Frazier Life Sciences Public Fund had purchased about $20m of its existing shares.

Read more
25 Oct 2021 16:03

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
22 Oct 2021 20:26

IN BRIEF: Silence Therapeutics reports solid progress across pipelines

IN BRIEF: Silence Therapeutics reports solid progress across pipelines

Read more
15 Oct 2021 15:40

CORRECT: Silence Therapeutics to delist from AIM; teams with Hansoh

CORRECT: Silence Therapeutics to delist from AIM; teams with Hansoh

Read more
15 Oct 2021 14:15

IN BRIEF: Silence Therapeutics to delist from AIM; unites with Hansoh

IN BRIEF: Silence Therapeutics to delist from AIM; unites with Hansoh

Read more
15 Oct 2021 12:23

Silence Therapeutics inks collaboration deal with Hansoh Pharmaceutical

(Sharecast News) - Silence Therapeutics announced a collaboration with Hansoh Pharmaceutical Group on Friday, to develop short interfering ribonucleic acids (siRNAs) for three undisclosed targets, leveraging its proprietary 'mRNAi GOLD' platform.

Read more
1 Sep 2021 09:30

Silence promotes John Strafford to head new product development

(Sharecast News) - Silence Therapeutics announced the appointment of John Strafford to the newly-created role of senior vice-president of business development, alliance management and new product development on Wednesday, effective immediately.

Read more
12 Aug 2021 13:56

IN BRIEF: Silence Therapeutics revenue up, new targets with AstraZeneca

IN BRIEF: Silence Therapeutics revenue up, new targets with AstraZeneca

Read more
12 Aug 2021 09:37

Silence Therapeutics losses widen as it progresses programmes

(Sharecast News) - Silence Therapeutics reported revenues from collaborations of £5.8m in its first half on Thursday, up from £1.1m year-on-year, which it put down to its work with AstraZeneca and Mallinckrodt.

Read more
5 Aug 2021 16:18

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.